This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Progress In Treating Cancer In The U.S. Continues To Surge, Surpassing 50 Million Life-years Saved

NEW YORK, Dec. 4, 2013 /PRNewswire/ -- U.S. life expectancy for people with cancer hit another all-time high, rising over 50 million life-years after diagnosis. The estimate of approximately 50 million life-years saved is based on the number of additional years of life that each person diagnosed with cancer since 1990 has experienced as a result of advances in science and broader access to novel cancer therapies. This is based on statistics collected through the Value of Medical Innovation initiative, led by the Center for Medicine in the Public Interest (CMPI), promoting a world free from cancer by 2050. CMPI cautions, however, that those gains could be at risk if the policy environment and healthcare system at large do not accelerate access to the innovations responsible for longer lives and declines in cancer-related death rates.

(Logo:  http://photos.prnewswire.com/prnh/20131204/NY27779LOGO )

According to CMPI co-founder Robert Goldberg, Ph.D., "The benefits of medical innovation to patients and their families can be counted in birthdays, anniversaries, weddings and other life events that would have been missed if it weren't for medical innovation."

In 1990, there were about six million cancer survivors in the United States. Today, there are about 14 million. Back then, about 57 percent of cancer patients could expect to live five years or more. Today, that number is nearly 70 percent. And the value that innovative therapies bring by way of longer life, productivity, consumer consumption of goods, increasing healthcare system efficiencies and societal prosperity is more than $4.8 trillion.

"We're at a turning point in battling cancer," said Scott Gottlieb, M.D., resident fellow for the American Enterprise Institute. "Doctors are finally able to reliably tailor treatments to the unique genetic composition of each patient's tumor rather than by its location in the body alone. Other new drugs are able to prime our own immune cells to attack cancers."

Research suggests that even greater gains in life-years—along with a decline in the cost of treating cancer—are possible through personalized medicine, which reduces the cost and time of treatment compared with the old one-size-fits-all model. "We shouldn't endanger the gains we've made and risk future advances by limiting or delaying access to the next generation of medicines," states Goldberg. "We can achieve a world free from cancer, but only if we continue to speed the development and use of innovations that have allowed us to reach 50 million life-years saved over the past two decades."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs